A global dialogue on non-amyloid targets for disease modification will take place on 21 October 2021 and gather international leaders across the research field to discuss future approaches to the development of disease modifying treatments as part of the dementia landscape project. This dialogue will be led by Dr Maria Carrillo, chief science officer, Alzheimer's Association, and Professor Philip Scheltens, professor of cognitive neurology and director, Alzheimer Center, Amsterdam University Medical Centers.
Thursday 21 October 2021
06:00 PDT San Francisco | 08:00 CDT Chicago | 09:00 EDT New York | 14:00 BST London | 15:00 CEST Central Europe
90 minutes
Chairs
Dr Maria Carrillo
Maria Carrillo is chief scientific officer at the Alzheimer’s Association (US), setting the strategic vision for the Association’s global research program. Dr Carrillo has published extensively on early diagnosis and biomarker standardization efforts, as well as on the global challenges to progress for research in Alzheimer’s and dementia. She is a co-author of the “Appropriate Use Criteria for Amyloid Imaging,” published by the Society of Nuclear Medicine and Molecular Imaging and the Alzheimer’s Association. Dr Carrillo earned her PhD from Northwestern University’s Institute for Neuroscience and completed a postdoctoral fellowship focused on Alzheimer’s brain imaging and risk factors at Rush University Medical Center in Chicago.
Professor Philip Scheltens
Philip Scheltens is professor of cognitive neurology and director of the Alzheimer Center, Amsterdam University Medical Centers (The Netherlands) and member of the World Dementia Council. His main clinical and research interests are Alzheimer's disease, vascular dementia, frontotemporal dementia, magnetic resonance imaging, PET imaging and fluid biomarkers. He is active in the field of biomarkers and clinical trials and has been the national PI for many studies, including phase 1-3 multicenter clinical trials. He founded and directs the Alzheimer Center since 2000, from which over 70 PhD theses have appeared since. In 2013, he co-founded the Dutch national plan against dementia (Deltaplan Dementie) and serves as the chair of its board.
Speakers
Dr Laurie Ryan
Dr. Laurie Ryan is Chief of the Clinical Interventions and Diagnostics Branch in the Division of Neuroscience at the National Institute on Aging, part of the NIH. She oversees the development, coordination, and implementation of the division’s clinical therapeutic and diagnostics research programs and infrastructure. Dr. Ryan also directs the Alzheimer’s disease and related dementias pharmacological clinical trials research portfolio. Dr. Ryan received her BA in Human Development from St. Mary’s College of Maryland in 1986 and her Masters in Psychology from Loyola College in Maryland in 1991. She undertook doctoral training in clinical psychology with specialty focus in neuropsychology at Louisiana State University in Baton Rouge. She completed a neuropsychology-focused psychology residency at the Medical University of South Carolina, Charleston and clinical neuropsychology fellowship at Thomas Jefferson University, Philadelphia. After completing her fellowship, Dr. Ryan joined the Defense and Veterans Brain Injury Center (DVBIC) at Walter Reed Army Medical Center in Washington, DC. In 2003, Dr. Ryan became the Assistant Director for Research where she was responsible for overseeing clinical research development and implementation with a particular focus on clinical trials. In September 2005, Dr. Ryan joined the NIA as the Program Director for Alzheimer’s clinical trials. In December 2013, she was promoted to the branch chief position.
Professor Malú Tansey
Norman and Susan Fixel Professor of Neuroscience and Neurology, Co-Director Center for Translational Research in Neurodegenerative Disease and the Parkinson’s Foundation Research Center. The research interests of our laboratory include investigating the role and regulation of immune and inflammatory mechanisms that protect against or predispose and individual to develop neurodegenerative disorders. Genetic and environmental contributions to lysosomal dysfunction and alterations in lipid signaling that dysregulate neuroimmune activity and trigger neuroinflammation are a main focus of investigation; as is the role of the gut-brain axis and chronic peripheral inflammation in the pathogenesis and progression of neurodegeneration.
Other dialogues in the series
To inform the dementia landscape report, the Council has hosted global dialogues for international dementia leaders focusing on key themes of research, care and prevention that were identified at the London dementia summit in 2013, as well as on additional key themes and new policy priorities that we have agreed to highlight in the report. See below for other upcoming dialogues.